Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671243 | 1.00 | ALDH1A1 (0.47) | ALDH1A1POLBPTGESMAPTHPGD | |
| SCHEMBL1671955 | 0.84 | ALDH1A1 (0.51) | ALDH1A1POLBPTGES | |
| SCHEMBL1671952 | 0.84 | ALDH1A1 (0.51) | ALDH1A1POLBPTGES | |
| SCHEMBL11970126 | 0.83 | MLNR (0.49) | ALDH1A1POLBPTGESMAPTMEN1 | |
| SCHEMBL10170051 | 0.83 | MLNR (0.49) | ALDH1A1POLBPTGESMAPTMEN1 | |
| SCHEMBL1726188 | 0.81 | PTGES (0.44) | ALDH1A1POLBPTGES | |
| SCHEMBL1726190 | 0.81 | PTGES (0.44) | ALDH1A1POLBPTGES | |
| SCHEMBL1671172 | 0.80 | ALDH1A1 (0.50) | ALDH1A1PTGESMAPTHPGDMEN1 | |
| SCHEMBL1671171 | 0.80 | ALDH1A1 (0.50) | ALDH1A1PTGESMAPTHPGDMEN1 | |
| SCHEMBL11970148 | 0.79 | PTGES (0.48) | ALDH1A1POLBPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | ALDH1A1 228/4885POLB 2618/4885PTGES 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.